



PRESS RELEASE: PARIS. October 10, 2016: Theranexus has obtained an orphan drug designation from the FDA for THN102 in the treatment of narcolepsy.

We are pleased to inform you that Theranexus, a CEA Life Sciences' [spin-off](#), exploiting the CEA/BMSystems' [copatent WO/2010/029131](#) in CNS therapeutics, obtained an orphan drug designation from the FDA for THN102 (in Phase II) in the treatment of narcolepsy. Download the official [Theranexus' press release](#).

Some news about BMSystems.

With an average of [5%-10% failure rate](#), all R&D managers and CEOs absolutely need to de-risk their businesses and to create cost-effective novel solutions for *medicine, health technologies, nutrition and cosmetics*.

Some of them are fully convinced [there is a solution!](#)

Every single researcher who accepts to think and do out of the box can succeed! [This really is possible!](#)

Do not hesitate to meet us in Paris at [HelloTomorrow](#) (October 13, 2016) the Global Innovation Summit, or at [Cosmetic-360](#) (October 14, 2016) the International R&D cosmetics conference.

In the meantime, we warmly invite you to read:

- the latest Stanford University (METRICS) [paper in JAMA](#) "What Happens When Underperforming Big Ideas in Research Become Entrenched?" about research integrity, and
- the [summary](#) and the [inaugural presentation](#) given by BMSystems' CEO at the BioEntrepreneur forum in 2015. The title of the keynote presentation: "The future will be digital and biology... but who will lead, and how!"

Best regards

Manuel GEA
CEO & VP R&D IT Bio-Modeling Systems

BMSystems, the world's first Mechanisms-Based Medicine company, Created in 2004, profitable since 2006, thanks to our recurrent clients, our patented collaborative discoveries already led to:

1. [A world's first](#) in neurodegenerative diseases ([publication](#)) with 2 awards in the US and Europe
2. [Pherecydes-Pharma](#): BMSystems' spin-off, [MR infections therapies, publication](#), in [Phase I/II](#),
3. Theranexus, a CEA Life Sciences' [spin-off](#) exploiting the CEA/BMSystems' [copatent WO/2010/029131](#) in CNS therapies, [Phase II entry](#) of THN102,

We invented CADI Discovery, the world's first and to date only operational "Mechanisms-based Medicine" analytical platform that proposes robust decision making support for R&D and Business:

1. *GO-NO GO decision before product acquisition or for portfolio risk analysis.*
2. *GO-NO GO decision before next development phase.*
3. *R&D program Rescue for a program facing critical issues during its lifetime.*
4. *External R&D B plan program when the A plan cannot be rescued to discover novel diagnostics & therapies.*
5. *Exploratory Discovery program to generate novel causal mechanism concepts to discover novel diagnostics & therapies.*

We changed the discovery paradigm to create novel medical meanings from unreliable heterogeneous sources of data.

We warmly invite you to download our [Short](#) Presentation (recommended) or our [Full](#) Presentation with the working principles and the 10 POCs exposed in details.

For more information: www.bmsystems.net

Authors LinkedIn Posts: <https://www.linkedin.com/today/posts/manuelgea>

I should be very happy if you accept to join my networks

- <https://www.linkedin.com/in/manuelgea>
- <https://twitter.com/manuelgea>